Shanghai Medicilon Inc
SSE:688202
Shanghai Medicilon Inc
Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. The company is headquartered in Shanghai, Shanghai and currently employs 2,440 full-time employees. The company went IPO on 2019-11-05. The firm is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The firm's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The firm provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. The company is headquartered in Shanghai, Shanghai and currently employs 2,440 full-time employees. The company went IPO on 2019-11-05. The firm is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The firm's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The firm provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
